tiprankstipranks
Trending News
More News >
Healthy Extracts (HYEX)
OTHER OTC:HYEX
US Market

Healthy Extracts (HYEX) AI Stock Analysis

Compare
7 Followers

Top Page

HYEX

Healthy Extracts

(OTC:HYEX)

Select Model
Select Model
Select Model
Neutral 56 (OpenAI - 4o)
Rating:56Neutral
Price Target:
Healthy Extracts' stock reflects a moderate score driven primarily by its financial performance and technical analysis. While the company shows revenue growth potential, persistent profitability challenges and high leverage are significant risks. The stock's technical indicators suggest a bullish trend, but overbought conditions warrant caution. The negative P/E ratio and lack of dividends further impact the overall score.
Positive Factors
Revenue Growth
The company has demonstrated a significant improvement in revenue, indicating strong market demand and effective sales strategies, which are crucial for long-term growth and market expansion.
Cash Flow Improvement
Positive free cash flow suggests better cash management and operational efficiency, providing the company with more flexibility to invest in growth opportunities and reduce financial risks.
Strategic Partnerships
Strategic partnerships enhance distribution networks and product visibility, supporting long-term revenue growth and competitive positioning in the nutraceutical market.
Negative Factors
High Leverage
High financial leverage increases risk, potentially limiting the company's ability to invest in growth and manage economic downturns, impacting long-term financial stability.
Profitability Challenges
Ongoing profitability issues, despite revenue growth, highlight operational inefficiencies and the challenge of converting sales into sustainable profits, affecting long-term viability.
Negative Net Income
Consistent negative net income underscores the difficulty in achieving profitability, which can hinder reinvestment in business growth and innovation over the long term.

Healthy Extracts (HYEX) vs. SPDR S&P 500 ETF (SPY)

Healthy Extracts Business Overview & Revenue Model

Company DescriptionHealthy Extracts Inc., through its subsidiaries, researches, develops, and markets natural plant-based products in the United States and internationally. It offers heart health nutritional supplements; and neuro products under the KETONOMICS name that enhance brain health, including memory, cognition, focus, and neuro-energy. The company also provides bergamot products in capsule form under the BergaMet Pro+, BergaMet Mega+O, BergaMet HERHEART, BergaMet Cholesterol Command, and BergaMet SPORTSHEART products labels. It distributes bergamot products through its website and distribution sites. The company was formerly known as Grey Cloak Tech Inc. and changed its name to Healthy Extracts Inc. in October 2020. Healthy Extracts Inc. was incorporated in 2014 and is based in Littleton, Colorado.
How the Company Makes MoneyHealthy Extracts makes money primarily through the sale of its nutraceutical products. The company generates revenue by selling directly to consumers through its e-commerce platform and by distributing its products through various retail and online channels. Key revenue streams include the sales of their branded supplements and custom formulations. The company also benefits from strategic partnerships with other health and wellness brands, which help expand its distribution network and increase product visibility. Additionally, Healthy Extracts may engage in licensing agreements for their proprietary formulations, providing another revenue source.

Healthy Extracts Financial Statement Overview

Summary
Healthy Extracts shows potential in revenue growth, yet struggles with profitability and financial leverage. The improvement in cash flow is promising, but the persistent negative earnings and high leverage present ongoing risks.
Income Statement
45
Neutral
Healthy Extracts has shown a significant improvement in revenue over the years, with a notable revenue growth from 2023 to 2024. However, the company still struggles with profitability, reporting a negative net income and EBIT consistently, indicating ongoing operational challenges. While gross profit margins are positive, the persistent negative net profit margins highlight the difficulty in converting sales to profit.
Balance Sheet
40
Negative
The company's balance sheet indicates a high level of debt relative to equity, with a concerning debt-to-equity ratio that reflects financial leverage risks. Despite this, the equity ratio is positive, suggesting some degree of financial stability. Nonetheless, the declining stockholders' equity over recent years poses a risk to financial health.
Cash Flow
50
Neutral
Cash flow statements reveal an improvement in operating cash flow with a positive free cash flow in the latest year, marking a positive shift from previous periods of negative cash flow. However, the cash flow to net income ratio remains unfavorable due to the negative net income, indicating challenges in translating operational success to bottom-line profitability.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue3.59M3.11M2.49M2.25M1.47M1.28M
Gross Profit1.88M1.91M1.62M1.37M695.08K-578.44K
EBITDA-799.72K-183.15K-2.24M-910.71K-1.88M-2.49M
Net Income-1.17M-840.67K-2.47M-989.96K-2.04M-2.65M
Balance Sheet
Total Assets26.19M2.38M2.64M2.78M3.03M3.12M
Cash, Cash Equivalents and Short-Term Investments189.45K112.02K19.44K65.65K222.10K59.20K
Total Debt0.00941.90K1.13M593.52K342.62K177.62K
Total Liabilities0.001.97M1.68M902.79K558.84K261.61K
Stockholders Equity0.00410.38K954.59K1.88M2.47M2.85M
Cash Flow
Free Cash Flow-180.06K281.97K-415.75K-342.95K-997.30K-3.49M
Operating Cash Flow-160.76K281.97K-415.75K-334.96K-901.30K-3.48M
Investing Cash Flow-19.30K0.000.00-7.99K-96.00K-425.88K
Financing Cash Flow269.11K-189.39K369.54K239.52K1.16M3.83M

Healthy Extracts Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.99
Price Trends
50DMA
1.78
Positive
100DMA
2.13
Negative
200DMA
2.17
Negative
Market Momentum
MACD
-0.03
Positive
RSI
52.34
Neutral
STOCH
37.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYEX, the sentiment is Positive. The current price of 1.99 is above the 20-day moving average (MA) of 1.95, above the 50-day MA of 1.78, and below the 200-day MA of 2.17, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 52.34 is Neutral, neither overbought nor oversold. The STOCH value of 37.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HYEX.

Healthy Extracts Risk Analysis

Healthy Extracts disclosed 11 risk factors in its most recent earnings report. Healthy Extracts reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Healthy Extracts Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
56
Neutral
$33.57M-6.23-9.44%19.20%-19.98%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
51
Neutral
$37.84M-10.85-13.08%12.21%69.91%
48
Neutral
$23.43M-0.75-50.23%-15.61%-68.96%
46
Neutral
$27.11M-1.20-53.29%-65.77%38.61%
44
Neutral
$36.44M-5.79-16.67%-23.60%-179.33%
39
Underperform
$15.41M-0.62-63.82%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HYEX
Healthy Extracts
1.99
-1.26
-38.77%
RMTI
Rockwell Med
0.92
-1.09
-54.23%
SCYX
SCYNEXIS
0.64
-0.44
-40.74%
AYTU
Aytu BioScience
2.30
0.90
64.29%
CPIX
Cumberland Pharmaceuticals
2.53
0.41
19.34%
COSM
Cosmos Holdings
0.44
-0.26
-37.14%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 20, 2025